Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Eichler, M; Andreou, D; Golcher, H; Hentschel, L; Richter, S; Hohenberger, P; Kasper, B; Pink, D; Jakob, J; Ashmawy, H; Hettmer, S; Tuchscherer, A; Grube, M; Heidt, V; Jentsch, C; Pablik, J; Wardelmann, E; Kreitner, KF; Kneser, U; Tonus, C; Wimberger, P; Schoffer, O; Reichardt, P; Wartenberg, M; Eberlein-Gonska, M; Bornhäuser, M; Schmitt, J; Schuler, MK.
Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study.
Oncol Res Treat. 2021; 44(6):301-312
Doi: 10.1159/000516262
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Andreou Dimosthenis
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. METHODS: From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. RESULTS: Patients and survivors (n = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28-8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67-9.21). CONCLUSION: Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development.
- Find related publications in this database (using NLM MeSH Indexing)
- Certification - administration & dosage
- Germany - administration & dosage
- Humans - administration & dosage
- Prospective Studies - administration & dosage
- Sarcoma - administration & dosage
- Soft Tissue Neoplasms - administration & dosage
- Find related publications in this database (Keywords)
- Sarcoma care
- Sarcoma treatment and diagnosis
- Tumor board utilization
- Observational study
- Orphan disease